- Home
- IMAB vs AVTX Comparison
IMAB vs AVTX Comparison
Compare IMAB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- AVTX
- Stock Information
- Founded
- IMAB 2014
- AVTX 2011
- Country
- IMAB United States
- AVTX United States
- Employees
- IMAB N/A
- AVTX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- AVTX Health Care
- Exchange
- IMAB Nasdaq
- AVTX Nasdaq
- Market Cap
- IMAB 83.8M
- AVTX 90.9M
- IPO Year
- IMAB 2020
- AVTX 2015
- Fundamental
- Price
- IMAB $1.39
- AVTX $9.77
- Analyst Decision
- IMAB Strong Buy
- AVTX Buy
- Analyst Count
- IMAB 3
- AVTX 1
- Target Price
- IMAB $8.00
- AVTX $35.00
- AVG Volume (30 Days)
- IMAB 378.4K
- AVTX 13.3K
- Earning Date
- IMAB 08-28-2024
- AVTX 11-07-2024
- Dividend Yield
- IMAB N/A
- AVTX N/A
- EPS Growth
- IMAB N/A
- AVTX N/A
- EPS
- IMAB N/A
- AVTX N/A
- Revenue
- IMAB $3,492,091.00
- AVTX $807,000.00
- Revenue This Year
- IMAB N/A
- AVTX N/A
- Revenue Next Year
- IMAB N/A
- AVTX N/A
- P/E Ratio
- IMAB N/A
- AVTX N/A
- Revenue Growth
- IMAB N/A
- AVTX N/A
- 52 Week Low
- IMAB $0.99
- AVTX $3.95
- 52 Week High
- IMAB $2.54
- AVTX $45.12
- Technical
- Relative Strength Index (RSI)
- IMAB 63.28
- AVTX 53.54
- Support Level
- IMAB $1.02
- AVTX $8.49
- Resistance Level
- IMAB $1.50
- AVTX $10.20
- Average True Range (ATR)
- IMAB 0.10
- AVTX 0.65
- MACD
- IMAB 0.04
- AVTX 0.11
- Stochastic Oscillator
- IMAB 77.08
- AVTX 74.69
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).